1Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J,1997,18 : 394-413.
2Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACPASIM guidelines for the management of patients with chronic stable angina : executive summary and recommendations. Circulation, 1999,99:2829-2848.
3Lopaschuk GD, Belke DD, Gamble J, et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease.Biochim Biophys Acta, 1994,1213:263-276.
4Lopashuk GD, Stanley WC. Glucose metabolism in the ischemic heart. Circulation, 1997,95 : 313-315.
5Lopaschuk GD, Kozak R. Trimetazidine inhibits fatty aeidoxidation in the heart, Jmol Cell Cardiol, 1998,30 : AI 12.
6Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res,2000,86:580-588.
7Allibardi S, Chierchia SL, Margonato V, et al. Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts. Cardiovasc Drugs Ther, 1998,12:543-549.
8Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Comlmrison with prooranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol,1994,37:279-288.
同被引文献23
1Banach M, Rysz J, Goch A, et al. The role of trimetazidine after acute myocardial infarction [ J ]. Curr Vasc Pharmacol, 2008,6 (4) :282-291.
2Fragasso G, Salerno A, Spoladore R, et al. Metabolic therapy of heart failure [ J ]. Curr Pharm Des, 2008, 14 (25) :2582-2591.
3Detry J M, Leclercq P J . Trimetazidine European Multicenter Study versus propranolol in stable angina pectoris: contribution of Holter electrocardiographic ambulatory monitoring[J]. Am J Cardiol, 1995,76(6) :8-11.
4Marazzi G, Gebara O, Vitale C, et al. Effect of trimetazidine on quality of life in elderly patients with isehemic dilated cardiomyopathy [ J ]. Adv Ther, 2009,26 (4) : 455- 461.
5Fragasso G, Piatti P M, Monti L, et al. Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: evaluation of the protective role of the metabolic modulator trimetazidine[ J]. J Am Coll Cardiol, 2002,39(3) :413-419.
6Szwed H, Sadowski Z, Elikowski W, et al. Efficacy and safety of trimetazidine in combination with metoprolol in patients with stable effort angina pectoris. TRIMPOL II- double-blind, randomized, placebo-controlled, multicentre trial[ J ]. Eur Heart J, 2000,21 (5) :363.
7Hanania G, Haiat R, Olive T, et al. Coronary artery disease observed in general hospitals: ETTIC study. Comparison between trimetazidine and mononitrate isosorbide for patients receiving betablockers [ J ]. Ann Cardiol Angeiol, 2002,51 ( 5 ) : 268-274.
8Manchanda S C. Treatment of stable angina with low dose diltiazem in combination with the metabolic agent trimetazidine[J]. Int J Cardiol,2003,88( 1 ) :83-89.
9Marzilli M, Klein W W. Efficacy and tolerability of trime- tazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials [ J ]. Coron Artery Dis, 2003,14(2) :171-179.
10Anonymous. Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project Free Radicals [ J ]. Eur Heart J, 2000,21 ( 18 ) : 1537-1546.
